Countries
Institutions
Fields
Rankings
Compare

Search institutions, scholars, countries and publications

Sankore

Named after the University of Sankore in Timbuktu — one of the world’s oldest centres of learning. Every figure here is computed from work-level records in our own graph, never copied from a source’s summary count.

Built from

OpenAlex — works, authorships, subject classification
ROR — institutional identity
ORCID — researcher identity
Crossref — publisher confirmation

Browse

Countries
Institutions
Fields
Rankings
What we cover

Coverage is partial and says so. A country appears with its research output only once its works have been swept; until then the portal shows whatever the graph happens to hold for it and labels it as exactly that.

Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study

2025Journal of sickle cell disease.JournalOpen access

10.1093/jscdis/yoag020.001 Full text1 citations

Authors

20 authors across 12 institutions in 2 countries.

Santosh SarafFirst author
Shehu U. Abdullahi
- Aminu Kano Teaching Hospital (NG)
as printed: Shehu Abdullahi
Adeseye M. Akinsete
- University of Lagos (NG)
as printed: Adeseye Akinsete
Foluke A. Fasola
- University College Hospital, Ibadan (NG)
as printed: Foluke Fasola
Modupe Idowu
Sharon Pennington
Sheinei Alan
Marshall Stagg
Earl Fields
David Archer

Fields

Assignment is probabilistic — a work belongs to several fields in proportions.

Hemoglobinopathies and Related Disorderslevel 3 · 1.00
Folate and B Vitamins Researchlevel 3 · 0.00
Myeloproliferative Neoplasms: Diagnosis and Treatmentlevel 3 · 0.00

Sources

Several sources describing one work is the point — it means the record rests on more than one authority.

openalexseen September 9, 2026
2025 · Journal of sickle cell disease. · 1 citations
https://openalex.org/W4417022388

Geoffrey AllenSenior author

Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study · Sankore